<DOC>
	<DOCNO>NCT00538889</DOCNO>
	<brief_summary>To assess safety tolerability lecozotan SR citalopram coadministred healthy subject .</brief_summary>
	<brief_title>Study Evaluating Combined Administration Lecozotan SR Citalopram Young Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Signed date IRB/IECapproved inform consent form studyspecific screening procedure perform . Men woman age 18 50 year , inclusive , screen . Women nonchildbearing potential , define surgically sterile postmenopausal &gt; 1 year , may include . For woman 50 year age , least two year retrospective amenorrhea FSH &gt; 38 estrogen &lt; 20 require . Body mass index ( BMI ) range 18.0 30.0 kg/m2 body weight great equal 50 kg . BMI calculate take subject 's weight , kilogram , divide square subject 's average height , meter , screening : BMI = weight ( kg ) / ( height [ ] ) 2 Presence history disorder may prevent successful completion study . Any clinically important deviation normal limit physical examination , vital sign , 12lead ECGs , clinical laboratory test result . Hypersensitivity citalopram inactive ingredient citalopram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Adult</keyword>
</DOC>